Acuitas Therapeutics


6190 Agronomy Road, Suite 402 Vancouver BC V6T 1Z3 Canada

Facebook: @Acuitas
Twitter: @Acuitastx
Acuitas: noun, insight, perception, sharpness.


Acuitas Scientists, in Collaboration With Other Researchers, Have Published Extensively on LNP Development and Characterization.


Huysmans et al. (2019) “Expression Kinetics and Innate Immune Response after Electroporation and LNP-Mediated Delivery of a Self-Amplifying mRNA in the Skin” Mol Ther.Nucleic Acids DOI: 10.1016/j.omtn.2019.08.001

Pardi et al. (2019) “Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques” Mol Ther.Nucleic Acids DOI: 10.1016/j.omtn.2019.03.003

Conway et al. (2019) “Non-viral delivery of zinc finger nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets” Mol Ther DOI: 10.1016/j.ymthe.2019.03.003

Parhiz et al (2018) “PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake” J Control Release DOI:10.1016/j.jconrel.2018.10.015

Pardi et al. (2018b) “Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies”  Nature Communications DOI:10.1038/s41467-018-05482-0

Pardi et al. (2018a) “Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses” Journal of Experimental Medicine DOI:10.1084/jem.20171450

Lutz et al. (2017) “Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines” NPJ Vaccines DOI:10.1038/s41541-017-0032-6

Thran et al. (2017) “mRNA mediates passive vaccination against infectious agents, toxins, and tumors” EMBO Molecular Medicine DOI:10.15252/emmm.201707678

Pardi et al. (2017b) Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge Nature Communications DOI:10.1038/ncomms14630

Pardi et al. (2017a) Zika virus protection by a single low-dose nucleoside-modified mRNA Vaccination” Nature DOI:10.1038/nature21428

Pardi et al. (2015) Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes J Controlled Release DOI:10.1016/j.jconrel.2015.08.007

Thess et al. (2015) Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals Mol Ther DOI:10.1038/mt.2015.103

Mui et al. (2013) “Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles” Mol Ther Nucleic Acids DOI:10.1038/mtna.2013.66

Maier et al. (2013) “Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics” Mol Ther DOI:10.1038/mt.2013.124

Jayaraman et al. (2012) “Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo” Angew Chem Int Ed Engl DOI:10.1002/anie.201203263

Semple et al. (2010) “Rational design of cationic lipids for siRNA delivery” Nat Biotechnol DOI:10.1038/nbt.1602

Akinc et al. (2010) “Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms” Mol Ther DOI:10.1038/mt.2010.85